Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984873 | 0.80 | KCNJ1 (0.67) | NPC1RAB9AMAPTALDH1A1CHRNB2 | |
| SCHEMBL3964365 | 0.79 | HPGDS (0.58) | — | |
| SCHEMBL28056039 | 0.77 | KCNJ1 (0.47) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16412236 | 0.77 | KCNJ1 (0.44) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18731512 | 0.76 | KCNJ1 (0.45) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL16159319 | 0.76 | HPGDS (0.55) | PSMB8 | |
| SCHEMBL6738366 | 0.75 | TSHR (0.76) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4330245 | 0.75 | NPC1 (0.61) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5201307 | 0.75 | HPGDS (0.50) | CYP3A4MAPK1 | |
| SCHEMBL27743881 | 0.75 | CYP1A2 (0.59) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| CN-101316853-B | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-103145738-A | Imidazo [2,1-b] thiayole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2013-06-12 | — | — | CN | disclosed |
| CN-101326155-B | Propionamide compounds as antiinflammatory agents | HOFFMANN LA ROCHE | 2012-06-20 | — | — | CN | disclosed |
| CN-101326155-A | Propionamide compounds as antiinflammatory agents | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | CN | disclosed |
| CN-101316853-A | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-101282761-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282974-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101277963-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-101277965-A | Imidazo [2, 1-b ] thiazole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-01 | — | — | CN | disclosed |
| EP-1960351-A1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065821-A1 | PROPIONAMIDE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| CN-1509291-A | Oxazolo-and-furopyrimidines and their use in medicaments against tumors | ��˹��ŵ�� | 2004-06-30 | — | — | CN | disclosed |
| US-5770615-A | Catecholamine surrogates useful as β3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5514809-A | METHINE DYES; BENZOTHIAZOLE DERIVATIVES; SENSITIZERS; AGING PRESERVABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| US-5374643-A | Aryl urea (thiourea) and cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| EP-0587180-A2 | Aryl urea (Thiourea) and cyanoguanidine derivatives | E.R. SQUIBB & SONS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | NPC1 66/4885RAB9A 3766/4885MAPT 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.